BACKGROUND: Herpes simplex virus (HSV) suppressive therapy reduces genital and plasma human immunodeficiency virus type 1 (HIV-1) RNA over periods up to 3 months, but the long-term effect is unknown. METHODS: A total of 484 HIV-1 and HSV type 2 seropositive Tanzanian women aged 16-35 years were enrolled in a randomized placebo-controlled trial of acyclovir administered at a dosage of 400 mg twice daily. Cervico-vaginal lavage and blood samples were collected at 6 months, 12 months, and 24 months for quantification of genital and plasma HIV-1 RNA and genital HSV DNA. Primary outcomes were detection and quantity of cervico-vaginal HIV-1 RNA at 6 months. RESULTS: At 6 months, there was little difference between the acyclovir and placebo arms for cervico-vaginal HIV-1 RNA detection (88 [ 41 .3%] of 213 vs 84 [ 44 .0%] of 191; odds ratio [OR], 0.90; 95% confidence interval [CI], 0.60-1.33), HSV DNA detection (20 [ 9 .4%] of 213 vs 22 [ 11 .5%] of 191; OR, 0.80; 95% CI, 0.42-1.51), genital HIV or HSV loads, or plasma HIV-1 RNA load. Estimated median adherence was 91%. There was a suggestion of an impact on cervico-vaginal HIV-1 RNA detection among women with estimated adherence 90% (OR, 0.74; 95% CI, 0.50-1.09) when data from all 3 visits were included. CONCLUSIONS: Acyclovir administered at a dosage of 400 mg twice daily is unlikely to be a useful long-term intervention to reduce HIV transmission. The lack of effect on HIV may be attributable to suboptimal adherence or treatment regimen.
BACKGROUND: Herpes simplex virus (HSV) suppressive therapy reduces genital and plasma human immunodeficiency virus type 1 (HIV-1) RNA over periods up to 3 months, but the long-term effect is unknown. METHODS: A total of 484 HIV-1 and HSV type 2 seropositive Tanzanian women aged 16-35 years were enrolled in a randomized placebo-controlled trial of acyclovir administered at a dosage of 400 mg twice daily. Cervico-vaginal lavage and blood samples were collected at 6 months, 12 months, and 24 months for quantification of genital and plasma HIV-1 RNA and genital HSV DNA. Primary outcomes were detection and quantity of cervico-vaginal HIV-1 RNA at 6 months. RESULTS: At 6 months, there was little difference between the acyclovir and placebo arms for cervico-vaginal HIV-1 RNA detection (88 [ 41 .3%] of 213 vs 84 [ 44 .0%] of 191; odds ratio [OR], 0.90; 95% confidence interval [CI], 0.60-1.33), HSV DNA detection (20 [ 9 .4%] of 213 vs 22 [ 11 .5%] of 191; OR, 0.80; 95% CI, 0.42-1.51), genital HIV or HSV loads, or plasma HIV-1 RNA load. Estimated median adherence was 91%. There was a suggestion of an impact on cervico-vaginal HIV-1 RNA detection among women with estimated adherence 90% (OR, 0.74; 95% CI, 0.50-1.09) when data from all 3 visits were included. CONCLUSIONS: Acyclovir administered at a dosage of 400 mg twice daily is unlikely to be a useful long-term intervention to reduce HIV transmission. The lack of effect on HIV may be attributable to suboptimal adherence or treatment regimen.
Authors: R H Gray; M J Wawer; R Brookmeyer; N K Sewankambo; D Serwadda; F Wabwire-Mangen; T Lutalo; X Li; T vanCott; T C Quinn Journal: Lancet Date: 2001-04-14 Impact factor: 79.321
Authors: H H Kessler; G Mühlbauer; B Rinner; E Stelzl; A Berger; H W Dörr; B Santner; E Marth; H Rabenau Journal: J Clin Microbiol Date: 2000-07 Impact factor: 5.948
Authors: R W Coombs; D J Wright; P S Reichelderfer; D N Burns; J Cohn; S Cu-Uvin; P A Baron; M H Cohen; A L Landay; S Lewis; A Kovacs Journal: J Infect Dis Date: 2001-09-13 Impact factor: 5.226
Authors: F X Mbopi-Kéou; G Grésenguet; P Mayaud; H A Weiss; R Gopal; M Matta; J L Paul; D W Brown; R J Hayes; D C Mabey; L Bélec Journal: J Infect Dis Date: 2000-09-08 Impact factor: 5.226
Authors: S B Mostad; J K Kreiss; A J Ryncarz; K Mandaliya; B Chohan; J Ndinya-Achola; J J Bwayo; L Corey Journal: J Infect Dis Date: 2000-01 Impact factor: 5.226
Authors: C Celum; A Wald; J R Lingappa; A S Magaret; R S Wang; N Mugo; A Mujugira; J M Baeten; J I Mullins; J P Hughes; E A Bukusi; C R Cohen; E Katabira; A Ronald; J Kiarie; C Farquhar; G J Stewart; J Makhema; M Essex; E Were; K H Fife; G de Bruyn; G E Gray; J A McIntyre; R Manongi; S Kapiga; D Coetzee; S Allen; M Inambao; K Kayitenkore; E Karita; W Kanweka; S Delany; H Rees; B Vwalika; W Stevens; M S Campbell; K K Thomas; R W Coombs; R Morrow; W L H Whittington; M J McElrath; L Barnes; R Ridzon; L Corey Journal: N Engl J Med Date: 2010-01-20 Impact factor: 91.245
Authors: Christophe Vanpouille; Andrea Lisco; Jean-Charles Grivel; Leda C Bassit; Robert C Kauffman; Jorge Sanchez; Raymond F Schinazi; Michael M Lederman; Benigno Rodriguez; Leonid Margolis Journal: Clin Infect Dis Date: 2015-03-03 Impact factor: 9.079
Authors: Deborah Watson-Jones; Anna Wald; Connie Celum; Jairam Lingappa; Helen A Weiss; John Changalucha; Kathy Baisley; Clare Tanton; Richard J Hayes; Joshua O Marshak; Rula Green Gladden; David M Koelle Journal: J Clin Microbiol Date: 2010-08-11 Impact factor: 5.948
Authors: Aziz Alami Chentoufi; Xavier Dervillez; Pierre-Alain Rubbo; Tiffany Kuo; Xiuli Zhang; Nicolas Nagot; Edouard Tuaillon; Philippe Van De Perre; Anthony B Nesburn; Lbachir Benmohamed Journal: Curr Trends Immunol Date: 2012